Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BPTF | Q12830 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9040661 | 1.00 | ATM (0.56) | ATMGAAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL423972 | 0.97 | — | — | |
| SCHEMBL11406639 | 0.92 | — | — | |
| SCHEMBL8642977 | 0.85 | — | — | |
| SCHEMBL10972781 | 0.85 | ALDH1A1 (0.50) | ATMGAAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL8663123 | 0.80 | ATM (0.48) | ATMGAAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL14349488 | 0.80 | ATM (0.59) | ATMGAAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5303517 | 0.79 | ATM (0.65) | ATMGAAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL13772749 | 0.79 | MEN1 (0.58) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL13772727 | 0.79 | MEN1 (0.58) | ALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153665-A | Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments | 拜耳医药股份有限公司 | 2019-01-04 | — | — | CN | claimed |
| EP-3221300-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-09-27 | — | — | EP | claimed |
| CN-107001300-A | Antibacterial benzothiazole derivatives | 埃科特莱茵药品有限公司 | 2017-08-01 | — | — | CN | claimed |
| EP-3083567-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2016-10-26 | — | — | EP | claimed |
| WO-2016079688-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-26 | — | — | WO | claimed |
| WO-2015091741-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-25 | — | — | WO | claimed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| EP-1962846-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007059323-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | claimed |
| EP-0454501-B1 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | SANKYO CO (JP) | 2001-09-05 | — | — | EP | claimed |
| EP-1070046-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | claimed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| WO-1999051564-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | claimed |
| EP-0512901-B1 | Aminated polycyclic compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-06-23 | — | — | EP | claimed |
| EP-0591040-B1 | Quaternary basic amides as tachykinines antagonists | SANOFI SA (FR) | 1999-02-03 | — | — | EP | claimed |
| EP-0474561-B1 | Arylalkylamines, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1998-12-09 | — | — | EP | claimed |
| EP-0839812-A1 | Preparation of benzylthiazolidine derivatives | Sankyo Company Limited (JP) | 1998-05-06 | — | — | EP | claimed |
| EP-0454501-A2 | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides | Sankyo Company Limited (JP) | 1991-10-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | ATM 4786/4885GAA 1247/4885ALDH1A1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.